SPC clarifies on the contract governing law in Hong Kong and Macao investments in the Greater Bay Area / CLP Reference: 1450/25.02.13 ; Promulgated: 2025-02-13 ; Effective: 2025-02-14 ...

U.S. markets; Revisions to the Anti-Unfair Competition Law address challenges to fair competition; China's data centers in ...

China has been singled out because the SEC found that “55% of foreign private issuers were traded only in the United States, and of those, the majority were Chinese firms incorporated in the Cayman ...

Anti-Unfair Competition Law revised prohibiting abuse of dominant positions. First national regulation draft on commercial mediation issued. MOF clarifies accounting treatment of foreign-invested ...

Main contents: The current revision focuses on implementation of the “safe harbor” system set forth in the third paragraph of Article 18 of the Anti-Monopoly Law, refining the market share and ...

Main contents: A stock exchange shall establish an acquisition and restructuring committee (a “Committee”) to consider, in accordance with the law, applications by listed companies for offerings of ...

The intersection between intellectual property and artificial intelligence raises challenging and significant legal issues. AUTHOR examines China’s first case relating to the structure and parameters ...

Western companies concerned about China's demand for sensitive rare earths information; Irish data regulators target ...

Main contents: For the purposes of these Provisions, the phrase “rights holder taking appropriate confidentiality measures” means the reasonable confidentiality measures commensurate with factors such ...

(2) the total closing market value of the listed company’s stock on the Shanghai Stock Exchange exceeded RMB 10 billion on each of the 20 consecutive trading days prior to the date of the announcement ...

BYD has expanded greatly in the U.S. (and other countries) despite increased U.S.-China tensions. It opened a bus factory in California in 2013, and since 2014 has spent more than $1.7 million ...

U.S. President Donald Trump’s recent executive order on drug pricing is built around a Most Favored Nation pricing policy China’s pharmaceutical industry has evolved from primarily a license-in ...